Pharma Giant Looking for New Diseases to Treat with Drug Linked to Suicide

Many are outraged that Eli Lilly gave nonprofits $3.9 million in grants last year for medical courses to "educate" doctors about the pain-and-fatigue ailment fibromyalgia--more than it spent for diabetes and Alzheimer's which people already know they have. 


But finding new diseases to justify a drug's existence is the normal way pharma operates. 

Especially Lilly who agreed to pay $1.42 billion for illegal marketing of its anti-psychotic Zyprexa last month--$615 million for criminally promoting it for dementia--another $62 million to 32 states for illegal pediatric marketing and agreed to resolve Medicaid fraud investigations into "rebates" at the same time. (And how was your year?) 

And whose diabetes treatment Byetta is tanking since reports last summer of six deaths, at least two from pancreatitis. 

But Lilly's fibromyalgia-fighting drug, Cymbalta (duloxetine)--its second best seller after Zyprexa--is anything but normal. 

Starting with the death of 19-year-old Cymbalta test subject Traci Johnson in 2004--who  hanged herself in the Lilly Clinic in Indianapolis and had no history of mental problems--it has been beset by reports of baffling, rapid, unprovoked, and out of character suicides. 

A 37-year-old man described in the Feb. 2008 Journal of Clinical Psychopharmacology with a stable marriage and employment and no history of mental problems tried to kill himself with carbon monoxide two months after taking Cymbalta for back pain. "The patient was unable to state exactly why he wanted to commit suicide," write the four physician authors all with the Department of Psychiatry and Behavioral Sciences at the University of Kansas Medical Center who note he returned to normal when the drug was stopped. 

A 63-year-old man with no history of suicide attempts or ideation was similarly "unable to explain why he was having thoughts of wanting to die," say the authors after becoming suicidal two weeks after being put on Cymbalta for fatigue, insomnia and sadness. 

Last January, a Texas man prescribed Cymbalta for peripheral neuropathy because of a job that required him to be on his feet all day with no history mental problems "had a normal day at work, drove home, said he was going to grab a sandwich to his wife, and went and shot himself," his family wrote a reporter. 

In Feb. 2007, a 19-year-old Wisconsin college student recently put on Cymbalta "checked out books for a paper he was to write over the weekend," emailed his resume "to see if he could get a spot on Obama's team for the summer" and "then hung himself from his loft bed in his dorm," writes his family. One month earlier, a 21-year old Midwest college student, recently put on Cymbalta, took his own life three minutes after speaking to his family while driving home and sounding fine, the family wrote a reporter. 

Nor are incomprehensible and abrupt suicide attempts on Cymbalta a US phenomenon. 

Bilal Salem and Elie Karam of the Saint George Hospital University Medical Center in Beirut, Lebanon write of similar "suicidality in apparently nonsuicidal patients after starting or increasing Duloxetine," in the June 2008 Clinical Practice and Epidemiology in Mental Health. 

Approved as an antidepressant and for diabetic nerve pain in 2004--soon after the Johnson suicide thanks to an unfazed FDA--Cymbalta soon proved to be the "Swiss Army Knife" of Lilly drugs says its hometown paper the Indianapolis Star--approved for general anxiety disorder and maintenance treatment of depression in 2007, for fibromyalgia in 2008 and with approvals for chronic knee and low back pain expected shortly. 

In Europe it is in use for stress urinary incontinence but in the US its side effect of urinary retention landed Cymbalta on the FDA's first Potential Signals of Serious Risks danger list in 2008.  (FDA won't release suicidal rates from stress urinary incontinence trials says reporter Jeanne Lenzer on Slate, who estimates them as 400 per 100,000 person-years for middle aged women.) 

But some, like Shannon Brownlee, author of "Overtreated: Why Too Much Medicine Is Making Us Sicker and Poorer," question the revenue-driven prescribothan. Should drugs  "that may have a really serious side effect called suicide," be used for simple knee or back pain, she asks in the Star. 

No kidding!  Cymbalta is also being studied for binge eating, social phobia, chronic fatigue, restless legs disorder, seasonal affective disorder, migraines, attention deficit disorder and childhood depression--despite known pediatric risks--PMS, menopause, alcoholism, panic disorder, obsessive compulsive disorder, kleptomania and the important medical condition: tennis elbow. 

At the American Academy of Pain Medicine Annual Meeting in January, Lilly presented a study by its own doctors finding Cymbalta was superior to placebo in knee pain--in keeping with its penchant to publish studies by Lilly funded and Lilly employed doctors saying Cymbalta is safe. 

Cymbalta is also a good use of state and third party payer dollars say Lilly funded doctors in "Differences In Medication Adherence and Healthcare Resource Utilization Patterns: Older Versus Newer Antidepressant Agents In Patients With Depression And/Or Anxiety Disorders" in the 2008-22 CNS Drugs who are fighting the "restrictive reimbursement policies for newer antidepressants," in which pharmacy benefits managers are saying you want us to spend WHAT? 

Getting benefits managers to cover the $200 a month cost for Cymbalta prescriptions for fibromyaglia  may also be tough since the ailment has no clear cause, blood test or cure.  Maybe Lilly will offer pointers in the medical courses it is funding.

Enjoy this piece?

… then let us make a small request. AlterNet’s journalists work tirelessly to counter the traditional corporate media narrative. We’re here seven days a week, 365 days a year. And we’re proud to say that we’ve been bringing you the real, unfiltered news for 20 years—longer than any other progressive news site on the Internet.

It’s through the generosity of our supporters that we’re able to share with you all the underreported news you need to know. Independent journalism is increasingly imperiled; ads alone can’t pay our bills. AlterNet counts on readers like you to support our coverage. Did you enjoy content from David Cay Johnston, Common Dreams, Raw Story and Robert Reich? Opinion from Salon and Jim Hightower? Analysis by The Conversation? Then join the hundreds of readers who have supported AlterNet this year.

Every reader contribution, whatever the amount, makes a tremendous difference. Help ensure AlterNet remains independent long into the future. Support progressive journalism with a one-time contribution to AlterNet, or click here to become a subscriber. Thank you. Click here to donate by check.

Close
alternet logo

Tough Times

Demand honest news. Help support AlterNet and our mission to keep you informed during this crisis.